Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 7/20 | 0.37 |
| ▸ | OPRM1 | P35372 | 6/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 6/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4018667 | 0.89 | FPR2 (0.39) | FPR2SCN9AHDAC6DRD4PARP10 | |
| SCHEMBL4017274 | 0.79 | PPARD (0.39) | PPARDOPRK1OPRM1OPRD1LMNA | |
| SCHEMBL4018970 | 0.78 | CARM1 (0.42) | PPARDOPRK1OPRM1OPRD1LMNA | |
| SCHEMBL4014189 | 0.77 | ROCK2 (0.40) | PPARDOPRK1OPRM1OPRD1LMNA | |
| SCHEMBL4016168 | 0.77 | ATM (0.45) | LMNAALDH1A1 | |
| SCHEMBL4019651 | 0.77 | PARP10 (0.40) | OPRK1OPRM1OPRD1LMNAHTT | |
| SCHEMBL4017097 | 0.76 | PPARD (0.42) | PPARDLMNAHTTCARM1PRMT6 | |
| SCHEMBL4024256 | 0.76 | DRD4 (0.46) | PPARDOPRK1OPRM1OPRD1HDAC6 | |
| SCHEMBL4024269 | 0.74 | LMNA (0.42) | PPARDOPRK1OPRM1OPRD1LMNA | |
| SCHEMBL13622917 | 0.69 | MAOB (0.44) | PPARDHTTCARM1PRMT6MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7618996-B2 | Diaryl ether derivatives and uses thereof | PFIZER INC. (US) | 2009-11-17 | — | — | US | claimed |
| EP-2064199-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | Pfizer Products Inc. (US) | 2009-06-03 | — | — | EP | claimed |
| WO-2008032156-A1 | DIARYL ETHER DERIVATIVES AND USES THEREOF | PFIZER PRODUCTS INC. (US) | 2008-03-20 | — | — | WO | claimed |
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | PFIZER INC | 2008-03-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070887-A1 | Diaryl Ether Derivatives and Uses Thereof | OPRD1, OPRK1, OPRL1 | FPR2 875/4885SCN9A 819/4885PPARD 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.